| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
Omeprazole sulfide-d3 has no direct pharmacological target as an internal standard. The unlabeled compound, omeprazole sulfide (also known as ufiprazole), is an inactive metabolite of the parent drug omeprazole. It is formed by the reduction of the sulfoxide group in the parent drug, a process that can occur chemically or metabolically. This metabolite has no significant activity as a proton pump inhibitor. As a standard, its use is purely analytical.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
As a stable isotope-labeled standard, Omeprazole sulfide-d3 is not tested for standalone in vitro activity. The parent drug, omeprazole, is a potent and selective inhibitor of the gastric H+/K+ ATPase (proton pump). Omeprazole sulfide is the inactive, ring-opened reduction product. In cell-based assays, its primary use is as an analytical standard to quantify the amount of parent drug metabolized or degraded via this pathway. |
| ln Vivo |
In vivo, omeprazole sulfide is an inactive metabolite of omeprazole. Following the administration of omeprazole, a portion is reduced to the sulfide form, which does not contribute to the acid-suppressing effects of the drug. It is primarily eliminated in the urine. The detection and quantification of this metabolite are important for understanding the complete metabolic fate and excretion profile of the parent drug, particularly in studies of drug metabolism and pharmacokinetics (DMPK).
|
| Enzyme Assay |
Omeprazole sulfide-d3 is used as an internal standard for non-cellular assays. For in vitro method development, a stock solution is prepared by dissolving the compound in an organic solvent like DMSO or methanol. A fixed, known amount of this standard is spiked into biological samples (e.g., plasma, urine, or microsomal incubations) before the sample preparation steps. After processing (e.g., protein precipitation, solid-phase extraction), the sample is analyzed by LC-MS/MS, and the signal from the unlabeled omeprazole sulfide is compared to the signal from the d3-labeled standard.
|
| Cell Assay |
Omeprazole sulfide-d3 is not used as a treatment in cell-based studies. Its role is as an analytical standard to quantify the unlabeled metabolite in cellular samples. For instance, primary human hepatocytes or liver microsomes are incubated with omeprazole. At various time points, the reaction is stopped, and a fixed amount of Omeprazole sulfide-d3 is added to the sample. The sample is then processed and analyzed by LC-MS to measure the amount of omeprazole sulfide formed, which provides a measure of the reduction pathway in that cellular model.
|
| Animal Protocol |
For in vivo animal experiments, Omeprazole sulfide-d3 is not administered to animals for efficacy. It is used as an analytical standard to measure the concentration of the unlabeled metabolite in samples from animal studies. For example, in a pharmacokinetic (PK) study, rats or dogs are administered omeprazole. Blood plasma is collected at multiple time points. The deuterated internal standard is added to these samples, and the concentration of omeprazole sulfide is determined by LC-MS. This data helps determine the metabolic clearance of the drug and the route of excretion.
|
| ADME/Pharmacokinetics |
Omeprazole sulfide-d3 is a stable isotope-labeled compound and has no independent pharmacokinetic parameters. The unlabeled omeprazole sulfide is a metabolite that is typically cleared from the body via renal excretion and further metabolism. Its appearance in plasma follows the dosing of omeprazole, and its elimination half-life is generally similar to or slightly longer than the parent drug, which has a half-life of 1-2 hours in humans.
|
| Toxicity/Toxicokinetics |
Omeprazole is a well-tolerated drug, and its primary inactive metabolite, omeprazole sulfide, is considered non-toxic at levels encountered in research. The deuterated standard is used in minute analytical quantities (micrograms to milligrams) and poses no additional toxic risk. Standard laboratory safety precautions should be observed when handling organic chemicals.
|
| References | |
| Additional Infomation |
Omeprazole sulfide-d3 is not a drug but a deuterium-labeled stable isotope internal standard. It is used primarily for research and development purposes, including method validation (AMV) and Quality Controlled (QC) applications for omeprazole. It is a critical tool for studying the metabolism, pharmacokinetics, and stability of omeprazole and other proton pump inhibitors, particularly for evaluating drug-drug interactions that affect its metabolic pathways.
|
| Molecular Formula |
C17H16D3N3O2S
|
|---|---|
| Molecular Weight |
332.44
|
| Exact Mass |
329.12
|
| CAS # |
922730-98-1
|
| PubChem CID |
45040155
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.884
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
387
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])OC1=CC2=C(C=C1)N=C(N2)SCC3=NC=C(C(=C3C)OC)C
|
| InChi Key |
XURCIPRUUASYLR-HPRDVNIFSA-N
|
| InChi Code |
InChI=1S/C17H19N3O2S/c1-10-8-18-15(11(2)16(10)22-4)9-23-17-19-13-6-5-12(21-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/i3D3
|
| Chemical Name |
2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfanyl]-6-(trideuteriomethoxy)-1H-benzimidazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (300.81 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0081 mL | 15.0403 mL | 30.0806 mL | |
| 5 mM | 0.6016 mL | 3.0081 mL | 6.0161 mL | |
| 10 mM | 0.3008 mL | 1.5040 mL | 3.0081 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
